Suzetrigine: A Non-Opioid Drug for Diabetic Nerve Pain Enters Phase 3

Reviewed by Sarim Mir, MD — Board-Certified Neurologist, Mir Neurology (Hagerstown & Cumberland, MD)

What changed

Most people with painful diabetic neuropathy are offered a familiar set of medications, and when those fall short, the options narrow quickly — sometimes ending with opioids that carry serious long-term risks. A potential new path is now being tested. Vertex Pharmaceuticals’ suzetrigine, a non-opioid pain medication, has moved into Phase 3 clinical trials for diabetic peripheral neuropathy after the FDA granted it Breakthrough Therapy designation for this use — a status reserved for therapies that may offer a meaningful advance over existing options.

It’s important to be precise about where things stand. Suzetrigine is already FDA-approved for short-term acute pain (such as pain after surgery) under the brand name Journavx. But for chronic diabetic nerve pain, it remains investigational: the Phase 3 program is designed to prove whether it works for this very different kind of pain, with results expected roughly in 2026–2027. Until those trials read out and the FDA acts, it is not approved for diabetic neuropathy.

A plain-English explainer of painful diabetic neuropathy

Diabetic peripheral neuropathy is nerve damage caused by years of elevated blood sugar. It typically begins in the feet and lower legs, because the longest nerves are the most vulnerable. When those damaged nerves misfire, they send pain signals that don’t reflect any real injury — producing burning, tingling, stabbing, or electric-shock sensations, often worse at night.

This is called neuropathic pain, and it behaves differently from the ordinary pain of a cut or a sprain. The nervous system itself has become overactive, which is one reason standard painkillers and even opioids often disappoint here. Chronic neuropathic pain is processed by the body in a fundamentally different way than the short-lived pain after surgery — a distinction that makes the Phase 3 diabetic-neuropathy trials so important.

How suzetrigine works, and why a non-opioid option matters

Suzetrigine targets a sodium channel called NaV1.8, which sits on the peripheral pain-sensing nerves and helps carry pain signals toward the brain. By selectively blocking this channel, the drug aims to dial down pain at the nerve level, before the signal ever reaches the brain. Because that channel is found mainly on peripheral pain nerves — not throughout the brain like opioids act — the goal is effective pain relief without the sedation, dependence, and overdose risk associated with opioids.

That difference is the whole point. Opioids work in the brain’s reward and pain pathways, which is exactly why they can be addictive and are a poor fit for a condition that may need treatment for years. A non-opioid medicine that relieves nerve pain without those risks would give patients and clinicians a safer long-term tool — especially valuable for people who can’t tolerate current neuropathy drugs or who want to avoid opioids entirely. Suzetrigine is one of several non-opioid approaches in development for chronic pain, but it is among the furthest along for diabetic neuropathy specifically.

When a diagnostic EMG is appropriate

Before any nerve-pain treatment — current or future — it helps to confirm what’s actually causing the symptoms. Burning or numb feet can come from diabetic neuropathy, but also from nerve compression, vitamin deficiencies, thyroid problems, or other neuropathies that call for different management. An EMG (electromyography) and nerve conduction study measures how well your nerves and muscles are sending signals, helping pinpoint the type and severity of nerve involvement.

A diagnostic EMG is often appropriate when symptoms are new, worsening, one-sided, or don’t fit a typical diabetic pattern, or when the cause is simply unclear. Getting that diagnosis right makes every later decision — including whether a patient might one day be a candidate for newer therapies — far more accurate.

What this means for you in Hagerstown & Cumberland

At Mir Neurology, the foundation of good neuropathy care is an accurate diagnosis. Dr. Sarim Mir performs in-office EMG and nerve conduction studies to clarify what’s driving your foot pain or numbness, then builds a management plan around proven treatments and good diabetes control — while keeping an eye on emerging options like suzetrigine as the evidence develops. Learn more about our neuropathy treatment and EMG testing.

If your feet burn, tingle, or feel numb, the first step is finding out why. We can help.

Call (301) 797-7600 to request an appointment, or request an appointment online.

Frequently asked questions

Can I get suzetrigine for my diabetic nerve pain now? Not for that use yet. Suzetrigine is FDA-approved for short-term acute pain, but for diabetic peripheral neuropathy it is investigational and still in Phase 3 trials, with results expected around 2026–2027. It is not currently approved for diabetic neuropathy.

How is it different from opioids? Suzetrigine blocks a specific sodium channel on peripheral pain nerves rather than acting on the brain’s opioid pathways. The aim is pain relief without the addiction and overdose risks linked to opioids.

Do I need an EMG before treating nerve pain? Often it helps. An EMG and nerve conduction study can confirm that your symptoms are diabetic neuropathy rather than another cause, which makes treatment safer and more targeted.

—

This article is for general education and is not a substitute for personalized medical advice from your own physician.

Sources: Solace Health — New Treatments for Chronic Pain